Challenges and issues in drug utilization research identified from the Latin American and African regions

Maribel Salas, Luciane C Lopes, Brian Godman, Ilse Truter, Abraham G Hartzema, Joseph Fadare, Johanita Burger, Kwame Appenteng, Macarius Donneyong, Ariel Arias, Daniel Ankrah, Olayinka O Ogunleye, Diana Gomez Galicia, Miriam del Carmen Garcia Estrada, Margaret N Oluka, Amos Massele, Luis Alesso, Raquel Herrera Comoglio, Jorgelina Bernet, Carmen Vilaseca & 3 others Martie S Lubbe, Laura Horne, Ulf Bergman

Research output: Contribution to conferenceAbstract

Abstract

Background: Despite advancements in drug utilization research (DUR), these have not been universal. Some regions such as the Latin America (LatAm) and African regions are facing challenges that are impeding the development of DUR. Objectives: To identify the main challenges and issues for DUR in the LatAm and African regions Methods: A collaborative initiative by the International Society of Pharmacoepidemiology Global Development Committee in partnership with the Latin America Drug Utilization Group and the Medicines Utilization Research in Africa Group was undertaken. A comprehensive literature review was conducted to identify local and international DUR publications. A core group of investigators and experts in DUR reviewed the publications and identified the main methodological challenges and issues. Subsequently, the group exchanged materials, participated in WebEx discussions, and reviewed the draft document. Results: Main issues: 1) Socioeconomic: high unemployment rate with poor standard of living, socioeconomic inequalities, low literacy levels, urban segregation, high migration rates, high rates of violent crime including drug trafficking and possession. 2) Healthcare-related: Disparities of social determinants of health, differences in the quality of public and private health sectors; and epidemiologic transition from communicable diseases to non-communicable diseases. Most health care systems are fragmented with variable access to medical care and medicines, and substandard record keeping. 3) Drug utilization-related: Inappropriate use of medicines including the elderly; limited infrastructure to reliably collect DU data; over-prescription of antimicrobials; polypharmacy; high rates of self-medication; and poor patient adherence (e.g. HIV/AIDS, diabetes mellitus and hypertension). Planning for DUR is affected by the multiplicity of drug distribution channels; trading in sub-standard, counterfeit medicines and insufficient quality control centers. Some publications are generated by local investigators, often suffering of methodological issues such as lack of representativeness of the population, limited data validity, and small sample sizes. Conclusions: There are common challenges for DUR when working within the LatAm and African regions. Based on our findings, the group is developing Guidance on Good Practices of Drug Utilization Research in those regions to assist researchers with issues pertaining to the planning, conduct, and evaluation of DUR.

Conference

Conference34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management 2018
Abbreviated titleICPE 2018
CountryCzech Republic
CityPrague
Period22/08/1826/08/18

Fingerprint

Drug Utilization
African Americans
Research
Latin America
Publications
Research Personnel
Counterfeit Drugs
Drug Utilization Review
Drug Trafficking
Pharmacoepidemiology
Healthcare Disparities
Social Determinants of Health
Polypharmacy
Self Medication
Unemployment
Private Sector
Crime
Patient Compliance
Quality Control
Sample Size

Keywords

  • drug utilisation research
  • Latin America
  • Africa
  • pharmacoeconomics

Cite this

Salas, M., Lopes, L. C., Godman, B., Truter, I., Hartzema, A. G., Fadare, J., ... Bergman, U. (Accepted/In press). Challenges and issues in drug utilization research identified from the Latin American and African regions. Abstract from 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management 2018, Prague, Czech Republic.
Salas, Maribel ; Lopes, Luciane C ; Godman, Brian ; Truter, Ilse ; Hartzema, Abraham G ; Fadare, Joseph ; Burger, Johanita ; Appenteng, Kwame ; Donneyong, Macarius ; Arias, Ariel ; Ankrah, Daniel ; Ogunleye, Olayinka O ; Galicia, Diana Gomez ; Garcia Estrada, Miriam del Carmen ; Oluka, Margaret N ; Massele, Amos ; Alesso, Luis ; Herrera Comoglio, Raquel ; Bernet, Jorgelina ; Vilaseca, Carmen ; Lubbe, Martie S ; Horne, Laura ; Bergman, Ulf. / Challenges and issues in drug utilization research identified from the Latin American and African regions. Abstract from 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management 2018, Prague, Czech Republic.3 p.
@conference{77f243adf36a464496cd20cd7b595b6c,
title = "Challenges and issues in drug utilization research identified from the Latin American and African regions",
abstract = "Background: Despite advancements in drug utilization research (DUR), these have not been universal. Some regions such as the Latin America (LatAm) and African regions are facing challenges that are impeding the development of DUR. Objectives: To identify the main challenges and issues for DUR in the LatAm and African regions Methods: A collaborative initiative by the International Society of Pharmacoepidemiology Global Development Committee in partnership with the Latin America Drug Utilization Group and the Medicines Utilization Research in Africa Group was undertaken. A comprehensive literature review was conducted to identify local and international DUR publications. A core group of investigators and experts in DUR reviewed the publications and identified the main methodological challenges and issues. Subsequently, the group exchanged materials, participated in WebEx discussions, and reviewed the draft document. Results: Main issues: 1) Socioeconomic: high unemployment rate with poor standard of living, socioeconomic inequalities, low literacy levels, urban segregation, high migration rates, high rates of violent crime including drug trafficking and possession. 2) Healthcare-related: Disparities of social determinants of health, differences in the quality of public and private health sectors; and epidemiologic transition from communicable diseases to non-communicable diseases. Most health care systems are fragmented with variable access to medical care and medicines, and substandard record keeping. 3) Drug utilization-related: Inappropriate use of medicines including the elderly; limited infrastructure to reliably collect DU data; over-prescription of antimicrobials; polypharmacy; high rates of self-medication; and poor patient adherence (e.g. HIV/AIDS, diabetes mellitus and hypertension). Planning for DUR is affected by the multiplicity of drug distribution channels; trading in sub-standard, counterfeit medicines and insufficient quality control centers. Some publications are generated by local investigators, often suffering of methodological issues such as lack of representativeness of the population, limited data validity, and small sample sizes. Conclusions: There are common challenges for DUR when working within the LatAm and African regions. Based on our findings, the group is developing Guidance on Good Practices of Drug Utilization Research in those regions to assist researchers with issues pertaining to the planning, conduct, and evaluation of DUR.",
keywords = "drug utilisation research, Latin America, Africa, pharmacoeconomics",
author = "Maribel Salas and Lopes, {Luciane C} and Brian Godman and Ilse Truter and Hartzema, {Abraham G} and Joseph Fadare and Johanita Burger and Kwame Appenteng and Macarius Donneyong and Ariel Arias and Daniel Ankrah and Ogunleye, {Olayinka O} and Galicia, {Diana Gomez} and {Garcia Estrada}, {Miriam del Carmen} and Oluka, {Margaret N} and Amos Massele and Luis Alesso and {Herrera Comoglio}, Raquel and Jorgelina Bernet and Carmen Vilaseca and Lubbe, {Martie S} and Laura Horne and Ulf Bergman",
year = "2018",
month = "5",
day = "8",
language = "English",
note = "34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management 2018, ICPE 2018 ; Conference date: 22-08-2018 Through 26-08-2018",

}

Salas, M, Lopes, LC, Godman, B, Truter, I, Hartzema, AG, Fadare, J, Burger, J, Appenteng, K, Donneyong, M, Arias, A, Ankrah, D, Ogunleye, OO, Galicia, DG, Garcia Estrada, MDC, Oluka, MN, Massele, A, Alesso, L, Herrera Comoglio, R, Bernet, J, Vilaseca, C, Lubbe, MS, Horne, L & Bergman, U 2018, 'Challenges and issues in drug utilization research identified from the Latin American and African regions' 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management 2018, Prague, Czech Republic, 22/08/18 - 26/08/18, .

Challenges and issues in drug utilization research identified from the Latin American and African regions. / Salas, Maribel; Lopes, Luciane C; Godman, Brian; Truter, Ilse; Hartzema, Abraham G; Fadare, Joseph; Burger, Johanita; Appenteng, Kwame; Donneyong, Macarius; Arias, Ariel; Ankrah, Daniel; Ogunleye, Olayinka O; Galicia, Diana Gomez; Garcia Estrada, Miriam del Carmen; Oluka, Margaret N; Massele, Amos; Alesso, Luis; Herrera Comoglio, Raquel; Bernet, Jorgelina; Vilaseca, Carmen; Lubbe, Martie S; Horne, Laura; Bergman, Ulf.

2018. Abstract from 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management 2018, Prague, Czech Republic.

Research output: Contribution to conferenceAbstract

TY - CONF

T1 - Challenges and issues in drug utilization research identified from the Latin American and African regions

AU - Salas, Maribel

AU - Lopes, Luciane C

AU - Godman, Brian

AU - Truter, Ilse

AU - Hartzema, Abraham G

AU - Fadare, Joseph

AU - Burger, Johanita

AU - Appenteng, Kwame

AU - Donneyong, Macarius

AU - Arias, Ariel

AU - Ankrah, Daniel

AU - Ogunleye, Olayinka O

AU - Galicia, Diana Gomez

AU - Garcia Estrada, Miriam del Carmen

AU - Oluka, Margaret N

AU - Massele, Amos

AU - Alesso, Luis

AU - Herrera Comoglio, Raquel

AU - Bernet, Jorgelina

AU - Vilaseca, Carmen

AU - Lubbe, Martie S

AU - Horne, Laura

AU - Bergman, Ulf

PY - 2018/5/8

Y1 - 2018/5/8

N2 - Background: Despite advancements in drug utilization research (DUR), these have not been universal. Some regions such as the Latin America (LatAm) and African regions are facing challenges that are impeding the development of DUR. Objectives: To identify the main challenges and issues for DUR in the LatAm and African regions Methods: A collaborative initiative by the International Society of Pharmacoepidemiology Global Development Committee in partnership with the Latin America Drug Utilization Group and the Medicines Utilization Research in Africa Group was undertaken. A comprehensive literature review was conducted to identify local and international DUR publications. A core group of investigators and experts in DUR reviewed the publications and identified the main methodological challenges and issues. Subsequently, the group exchanged materials, participated in WebEx discussions, and reviewed the draft document. Results: Main issues: 1) Socioeconomic: high unemployment rate with poor standard of living, socioeconomic inequalities, low literacy levels, urban segregation, high migration rates, high rates of violent crime including drug trafficking and possession. 2) Healthcare-related: Disparities of social determinants of health, differences in the quality of public and private health sectors; and epidemiologic transition from communicable diseases to non-communicable diseases. Most health care systems are fragmented with variable access to medical care and medicines, and substandard record keeping. 3) Drug utilization-related: Inappropriate use of medicines including the elderly; limited infrastructure to reliably collect DU data; over-prescription of antimicrobials; polypharmacy; high rates of self-medication; and poor patient adherence (e.g. HIV/AIDS, diabetes mellitus and hypertension). Planning for DUR is affected by the multiplicity of drug distribution channels; trading in sub-standard, counterfeit medicines and insufficient quality control centers. Some publications are generated by local investigators, often suffering of methodological issues such as lack of representativeness of the population, limited data validity, and small sample sizes. Conclusions: There are common challenges for DUR when working within the LatAm and African regions. Based on our findings, the group is developing Guidance on Good Practices of Drug Utilization Research in those regions to assist researchers with issues pertaining to the planning, conduct, and evaluation of DUR.

AB - Background: Despite advancements in drug utilization research (DUR), these have not been universal. Some regions such as the Latin America (LatAm) and African regions are facing challenges that are impeding the development of DUR. Objectives: To identify the main challenges and issues for DUR in the LatAm and African regions Methods: A collaborative initiative by the International Society of Pharmacoepidemiology Global Development Committee in partnership with the Latin America Drug Utilization Group and the Medicines Utilization Research in Africa Group was undertaken. A comprehensive literature review was conducted to identify local and international DUR publications. A core group of investigators and experts in DUR reviewed the publications and identified the main methodological challenges and issues. Subsequently, the group exchanged materials, participated in WebEx discussions, and reviewed the draft document. Results: Main issues: 1) Socioeconomic: high unemployment rate with poor standard of living, socioeconomic inequalities, low literacy levels, urban segregation, high migration rates, high rates of violent crime including drug trafficking and possession. 2) Healthcare-related: Disparities of social determinants of health, differences in the quality of public and private health sectors; and epidemiologic transition from communicable diseases to non-communicable diseases. Most health care systems are fragmented with variable access to medical care and medicines, and substandard record keeping. 3) Drug utilization-related: Inappropriate use of medicines including the elderly; limited infrastructure to reliably collect DU data; over-prescription of antimicrobials; polypharmacy; high rates of self-medication; and poor patient adherence (e.g. HIV/AIDS, diabetes mellitus and hypertension). Planning for DUR is affected by the multiplicity of drug distribution channels; trading in sub-standard, counterfeit medicines and insufficient quality control centers. Some publications are generated by local investigators, often suffering of methodological issues such as lack of representativeness of the population, limited data validity, and small sample sizes. Conclusions: There are common challenges for DUR when working within the LatAm and African regions. Based on our findings, the group is developing Guidance on Good Practices of Drug Utilization Research in those regions to assist researchers with issues pertaining to the planning, conduct, and evaluation of DUR.

KW - drug utilisation research

KW - Latin America

KW - Africa

KW - pharmacoeconomics

UR - https://www.pharmacoepi.org/meetings/annual-conference/2018-icpe/

M3 - Abstract

ER -

Salas M, Lopes LC, Godman B, Truter I, Hartzema AG, Fadare J et al. Challenges and issues in drug utilization research identified from the Latin American and African regions. 2018. Abstract from 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management 2018, Prague, Czech Republic.